ACOG Updates Maternal Immunization Guidance: Timing, Safety, and Co-Administration for Respiratory Season

Maternal immunization represents one of the most effective preventive interventions in modern perinatal medicine. In an updated Committee Statement developed by the Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group and published in Obstetrics & Gynecology, the American College of Obstetricians and Gynecologists (ACOG) reinforced routine antenatal administration of influenza, COVID-19, Tdap, and RSV vaccines.

Pregnancy alters systemic maternal immune regulation, diminishes lung volume, and increases cardiac output. These normal physiological adaptations increase the risk of severe acute respiratory complications, intensive care admissions, and preterm delivery when viral infections occur. Antenatal vaccination protects the pregnant patient directly while establishing transplacental antibody transfer to shield the vulnerable newborn.

Human newborns enter the world with an unprimed, developing immune system and cannot safely receive influenza or COVID-19 immunizations until six months of age. Maternal vaccination during pregnancy stimulates maternal production of specific IgG antibodies, which actively cross the placenta via Fc-receptor transport in the syncytiotrophoblast. This passive biological transfer provides the infant with immediate systemic defense throughout the highest-risk early months of life.

ACOG guidance categorizes maternal vaccines by gestational timing, formulation safety, and seasonal indication. Clinicians and midwives must tailor conversations around specific gestational checkpoints to ensure no immunizations are missed.

Influenza vaccination remains indicated in any trimester as soon as regional supplies arrive in autumn. While the FDA approved a novel mRNA influenza vaccine (mRNA-1010) for non-pregnant adults in 2026, ACOG specifies that mRNA influenza vaccines are not approved in pregnancy due to absent clinical trial safety data. Standard inactivated or recombinant influenza shots remain the sole indicated formulations.

For RSV protection, ACOG enacted an essential clinical change for the 2026-27 season: the seasonal window for maternal vaccination now extends through March 1, rather than concluding on January 31. This extension accounts for persistent late-winter viral circulation across southwestern and temperate climates. Clinicians must confirm patients receive the bivalent RSV PreF vaccine (Abrysvo). The adjuvanted RSV vaccine (Arexvy) is not approved in pregnancy.

To ensure seamless integration into routine obstetric care, ACOG recommends embedding maternal immunization checkpoints directly into standardized prenatal clinical workflows. Structured gestational milestone counseling prevents decision fatigue and clarifies expectations early in pregnancy.

Patients frequently express concern that receiving multiple injections during a single clinical encounter will overwhelm their immune system or cause severe systemic side effects. ACOG Practice Advisories provide clear reassurance: all vaccines recommended during pregnancy can be co-administered simultaneously with zero reduction in immunological response.

Clinical trials and extensive post-market safety surveillance confirm that co-administering COVID-19, influenza, RSV, and Tdap vaccines does not alter antibody conversion rates or compromise fetal safety. Systemic reactions following co-administration (such as transient low-grade fever, mild headache, or fatigue) mirror the incidence observed with individual administrations.

Best clinical practice dictates administering co-administered vaccines at distinct anatomical injection sites. For example, clinicians can administer influenza in the left deltoid and Tdap in the right deltoid. If three vaccines are indicated at a single encounter, clinicians can separate injections on the same arm by at least one inch. Bundling vaccines into scheduled prenatal visits eliminates travel burdens and ensures consistent patient protection.

ACOG's Committee Statement highlights that obstetrician-gynecologists, Certified Nurse-Midwives, and nurse practitioners represent the single most trusted source of vaccine guidance for pregnant individuals. The tone and structure of clinician counseling dictate patient confidence.

Trauma-informed communication begins with empathetic, non-judgmental listening. Clinicians should ask open-ended questions: 'What questions or concerns do you have about the vaccines recommended for your baby at this stage of pregnancy?' Rather than dismissing hesitation, clinicians validate patient caution as an expression of maternal care, while explaining the direct neonatal benefits of transplacental antibodies.

Disparities in maternal vaccination rates persist along socioeconomic and racial lines. Data show lower coverage rates among pregnant individuals covered by Medicaid, primarily driven by structural pharmacy deserts, transportation barriers, and confusing billing policies.

ACOG research underscores that when obstetric practices stock vaccines in-office and recommend them at the point of care, vaccine uptake increases five to fifty times compared to issuing paper prescriptions for outside retail pharmacies.

In Arizona, Certified Nurse-Midwives (CNMs) operate as licensed Advanced Practice Registered Nurses (APRNs) with full, independent prescriptive authority under Arizona Revised Statutes (A.R.S. § 32-1606). Midwives throughout Maricopa County, Pinal County, and the East Valley manage prenatal preventive protocols autonomously while maintaining seamless collaborative arrangements with hospital OB/GYN teams.

Midwifery practices integrated within regional medical centers, including Banner University Medical Center Phoenix, HonorHealth Scottsdale Shea, Valleywise Health, and Dignity Health Chandler Regional, routinely administer maternal vaccines during outpatient visits. When high-risk obstetric conditions arise, such as severe preeclampsia or threatened preterm labor prior to 32 weeks, CNMs and maternal-fetal medicine (MFM) specialists co-manage the patient.

Furthermore, Arizona hospital-based midwives emphasize coordinated continuity from prenatal clinics to pediatric care. If a patient delivers precipitously before the 32-week RSV vaccine window, the hospital clinical team ensures the newborn is identified for nirsevimab monoclonal antibody therapy prior to nursery discharge. This integrated collaborative model protects both maternal autonomy and infant safety.